 They also lead to cancers and resistance to therapies which aim to treat them.Patients with aberrant c-Met activity usually have a poor prognosis, aggressive disease, increased metastasis and shortened survival.This is why targeting the HGF/c-MET signalling pathway has been untaken as a treatment for cancer, and several different therapeutic approaches are being clinically tested.